NCT04395989: An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC

Breast Cancer Type: Triple Negative
Hormone Mutations: AR+
Other Mutations: HER2, PI3K, Akt, mTOR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy, Therapeutic Antibody, Serine-Threonine Kinase Inhibitor, Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic, untreated, or actively progressing CNS metastases

Comments are closed.

Up ↑